NRX-0305: A Pan-Mutant BRAF Degrader with Broad Preclinical Efficacy, Brain Penetrance, and Synergistic Potential with MEK Inhibition Across Class 1/2/3 BRAF-mutant Cancers By webmaster / April 25, 2025
Bexobrutideg (NX-5948) is a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader that Breaks Established Design Rules for CNS Drugs By webmaster / April 25, 2025
NX-5948 and NX-2127 Potently Degrade a Broad Array of Clinically-Relevant BTK Mutants That Display Resistance to Inhibitors and Other BTK Degraders By webmaster / March 25, 2025
IRAK4 Degrader GS-6791 Inhibits TLR And IL-1R-Driven Inflammatory Signaling, And Ameliorates Disease In A Preclinical Arthritis Model By aterrado@waterhousebrands.com / January 7, 2025
Small Molecule Inhibition Of The Ubiquitin Ligase CBL-B With NX-1607 Results In Potent T And NK Cell Mediated Anti-Tumor Response By aterrado@waterhousebrands.com / January 7, 2025
Initial Clinical Characterization Of Novel Proximal Biomarkers For NX-1607, A First-In-Class Oral CBL-B Inhibitor, In Patients With Advanced Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of The CBL-B E3 Ubiquitin Ligase, Promotes T And NK Cell Activation And Enhances NK-Mediated ADCC In A Mouse Lymphoma Tumor Model By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of CBL-B, Is Efficacious As A Single Agent And In Combination With Rituximab In Preclinical Mouse Models Of Lymphoma By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of CBL-B, Enhances Anti-PD-1-Mediated Tumor Growth Inhibition By Reshaping Intratumoral Innate And Adaptive Immune Responses By aterrado@waterhousebrands.com / January 7, 2025
NX-5948 Promotes Selective, Sub-Nanomolar Degradation Of Inhibitor-Resistant BTK Mutants By aterrado@waterhousebrands.com / January 7, 2025
